Xeris Biopharma Q3 EPS Forecast Decreased by HC Wainwright

Key Points

• HC Wainwright trimmed its Q3 2026 EPS estimate for Xeris Biopharma to $0.02 from $0.03, while keeping a Buy rating and a $10 price target on the stock.
• The company beat revenue expectations in its latest quarterly report, posting $83.13 million in revenue versus the $79.83 million consensus, though EPS came in at $0.01.
• Shares were trading at $6.53 on Monday, below the average analyst price target of about $10.80, and recent insider selling totaled 60,835 shares over the past 90 days.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Equities researchers at HC Wainwright decreased their Q3 2026 earnings per share (EPS) estimates for Xeris Biopharma in a report released on Friday, May 8th. HC Wainwright analyst B. Folkes now anticipates that the company will earn $0.02 per share for the quarter, down from their previous estimate of $0.03. HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Xeris Biopharma's current full-year earnings is $0.12 per share. HC Wainwright also issued estimates for Xeris Biopharma's Q4 2026 earnings at $0.02 EPS and FY2030 earnings at $0.93 EPS.

XERS has been the topic of a number of other reports. Weiss Ratings upgraded shares of Xeris Biopharma from a "sell (d-)" rating to a "hold (c-)" rating in a research report on Wednesday, March 4th. Wall Street Zen upgraded shares of Xeris Biopharma from a "buy" rating to a "strong-buy" rating in a research report on Saturday, March 7th. Four analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, Xeris Biopharma currently has an average rating of "Moderate Buy" and an average price target of $10.80.

Xeris Biopharma Stock Performance

Shares of XERS opened at $6.53 on Monday. The company has a current ratio of 2.12, a quick ratio of 1.50 and a debt-to-equity ratio of 17.00. The firm has a market cap of $1.13 billion, a PE ratio of 108.83 and a beta of 0.85. The company's 50 day simple moving average is $5.92 and its 200-day simple moving average is $6.96. Xeris Biopharma has a 12-month low of $4.30 and a 12-month high of $10.08.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter. The business had revenue of $83.13 million for the quarter, compared to analyst estimates of $79.83 million. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%.

Insider Activity at Xeris Biopharma

In other news, insider Beth Hecht sold 16,667 shares of the company's stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $6.23, for a total transaction of $103,835.41. Following the completion of the sale, the insider owned 1,193,173 shares in the company, valued at $7,433,467.79. This represents a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director James Aloysius Brady sold 10,834 shares of the company's stock in a transaction that occurred on Monday, March 30th. The stock was sold at an average price of $5.54, for a total value of $60,020.36. Following the sale, the director owned 89,166 shares of the company's stock, valued at $493,979.64. This trade represents a 10.83% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 60,835 shares of company stock valued at $367,860 in the last 90 days. Company insiders own 4.56% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in Xeris Biopharma by 13.8% during the fourth quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company's stock worth $87,815,000 after acquiring an additional 1,358,760 shares during the period. Geode Capital Management LLC grew its holdings in Xeris Biopharma by 3.3% in the fourth quarter. Geode Capital Management LLC now owns 4,275,989 shares of the company's stock valued at $33,571,000 after purchasing an additional 135,815 shares during the last quarter. State Street Corp grew its holdings in Xeris Biopharma by 10.1% in the fourth quarter. State Street Corp now owns 4,116,924 shares of the company's stock valued at $32,318,000 after purchasing an additional 378,595 shares during the last quarter. Qube Research & Technologies Ltd grew its holdings in Xeris Biopharma by 6.0% in the third quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company's stock valued at $26,657,000 after purchasing an additional 185,063 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Xeris Biopharma by 75.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company's stock valued at $15,317,000 after acquiring an additional 1,199,435 shares during the last quarter. Institutional investors and hedge funds own 42.75% of the company's stock.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company's proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company's flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.